LINTEX
920106
LINGOOD
833284
NTGEC
870436
CG MED EQUIP.
838810
Jiayu Holding
300117
CN Stock MarketDetailed Quotes
688202 Shanghai Medicilon Inc.
- 34.20
- -3.16-8.46%
Market Closed Feb 28 15:00 CST
4.61BMarket Cap-16.64P/E (TTM)
37.42High33.88Low64.27KlotVolume36.50Open37.36Pre Close227.39MTurnover4.77%Turnover RatioLossP/E (Static)134.67MShares51.1852wk High1.96P/B4.61BFloat Cap23.3052wk Low44.83Limit Up134.67MShs Float407.20Historical High29.89Limit Down9.48%Amplitude23.30Historical Low--Dividend TTM35.38Avg Price35.82KlotAsk--Div YieldTTM100Lot Size25.98KlotBid
Shanghai Medicilon Inc. News
Shanghai Medicilon Inc. (688202.SH): Has not yet repurchased company shares.
Gelonghui, February 28丨Shanghai Medicilon Inc. (688202.SH) announced that as of February 28, 2025, the company has not yet repurchased its shares through the centralized bidding trading method via the Shanghai Stock Exchange system.
Medici: Medici: 2024 Annual Results Report Announcement
Medici: 2024 Annual Results Report Announcement
Shanghai Medicilon Inc. (688202.SH): Net loss of 0.316 billion yuan for the year 2024.
Shanghai Medicilon Inc. (688202.SH) released its performance report for the year 2024, during the reporting period the company achieved revenue of 10...
Revenues Not Telling The Story For Shanghai Medicilon Inc. (SHSE:688202) After Shares Rise 32%
Shanghai Medicilon Inc.'s (SHSE:688202) Market Cap Increased by CN¥393m, Insiders Receive a 46% Cut
Medici: 2024 Annual Results Forecast
Shanghai Medicilon Appoints Chair, CFO; Shares Up 4%
It's Down 26% But Shanghai Medicilon Inc. (SHSE:688202) Could Be Riskier Than It Looks
Shanghai Medicilon Inc. (688202.SH): Recently, the prices of laboratory monkeys have stabilized.
On December 20, Gelonghui reported that Shanghai Medicilon Inc. (688202.SH) recently stated during an institutional investor research session that the prices of experimental monkeys have stabilized. The company has proactively taken various measures to ensure the stability of its supply of experimental animals, particularly experimental monkeys, by enriching procurement channels and deepening cooperation with suppliers of experimental animals, to meet the needs of its operation.
Shanghai Medicilon Inc. (688202.SH): The company has established a multi-point layout in key overseas industrial regions such as the USA, Europe, and the Asia-Pacific.
Gelonghui, December 20, Shanghai Medicilon Inc. (688202.SH) recently stated during an institutional investor survey that the company is establishing a multi-point layout in major overseas industry core regions such as the USA, Europe, and the Asia-Pacific, strengthening laboratory capabilities and building a business team. Currently, the company has over ten members in its BD team in the USA and will continue to enhance the BD team in the European market, increase communication between overseas BD and domestic research teams, establish a client information intelligence system, ensure effective management of major client services, and gradually build a market sales system that adapts to overseas market competition. In addition, the company will actively participate in overseas industry conferences, increasing the regular engagement of the research team.
Further Weakness as Shanghai Medicilon (SHSE:688202) Drops 8.2% This Week, Taking Three-year Losses to 85%
Is Shanghai Medicilon (SHSE:688202) Weighed On By Its Debt Load?
Medici: Medici: THIRD QUARTER REPORT 2024
Medici: Third quarter report 2024
shanghai medicilon inc. (688202.SH): net loss of 0.129 billion yuan in the first three quarters.
On October 30, shanghai medicilon inc. (688202.SH) announced that the company achieved revenue of 0.802 billion yuan in the first three quarters, a year-on-year decrease of 32.2%; net income attributable to the parent company was -0.129 billion yuan; non-recurring net profit attributable to the parent company was -0.142 billion yuan.
The Market Lifts Shanghai Medicilon Inc. (SHSE:688202) Shares 41% But It Can Do More
shanghai's three major leading industry mother funds have started, catalyzing CRO companies like shanghai medicilon inc. to embrace new opportunities for technological innovation.
Recently, Shanghai Guotou Leading Private Equity Fund Management Company officially launched the selection work for the sub-funds of the three leading industrial parent funds, aiming to enhance the development level of Shanghai's integrated circuits, biomedical, and ai industries, in order to promote the high-quality development of the Shanghai economy. As one of the economic centers of China, Shanghai, with biomedical as an important industry pillar, has nurtured many excellent research institutions and high-level pharmaceutical companies here. The scale of the Shanghai biomedical industry has grown from 103.46 billion yuan in 2008 to 600 billion yuan in 2020, with a compound annual growth rate of 15.8%.
Shanghai Medicilon Inc.'s (SHSE:688202) Market Cap Increased by CN¥767m, Insiders Receive a 46% Cut
Shanghai Medicilon Inc. (688202.SH): In August, the company did not repurchase shares.
On August 31, 2024, Medicilon Inc. (688202.SH) announced that it did not repurchase any shares in August 2024. As of August 31, 2024, the company has repurchased a total of 258,153 shares through the Shanghai Stock Exchange system, accounting for 0.1917% of the total share capital. The highest price at which the shares were repurchased was RMB 32.55 per share, and the lowest price was RMB 26.44 per share. The total amount paid was RMB 7,450,315.99 (excluding stamp duty, transaction fees, and other expenses).
